Year: 2017
Type: review
Abstract: The PD-1 and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced anti-tumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on anti-tumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for anti-tumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to anti-tumor immunity. Here we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating anti-tumor CD8+ T cell responses.
Source: Frontiers in Immunology
Authors: Rachel M. Gibbons Johnson, Haidong Dong
Institutions: University of Minnesota Morris, Mayo Clinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Funders: Howard Hughes Medical Institute, Mayo Clinic, Cancer Research Institute, Richard M. Schulze Family Foundation, University of Minnesota, National Institutes of Health, Center for Individualized Medicine, Mayo Clinic, National Cancer Institute, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W2742288460
